118374-47-3 Usage
General Description
Lysobactin is a small molecule antibiotic produced by the soil bacterium Streptomyces sp. that exhibits potent activity against a wide range of pathogens, including Gram-positive and Gram-negative bacteria, as well as Mycobacterium tuberculosis. The chemical structure of lysobactin contains a unique 13-membered macrocyclic lactam ring with four thiazole and thiazoline rings, and it is proposed to work by disrupting bacterial cell membrane integrity through a novel mechanism. Lysobactin has shown promising antimicrobial potential and is currently being studied for its therapeutic applications in various infectious diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 118374-47-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,8,3,7 and 4 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 118374-47:
(8*1)+(7*1)+(6*8)+(5*3)+(4*7)+(3*4)+(2*4)+(1*7)=133
133 % 10 = 3
So 118374-47-3 is a valid CAS Registry Number.
InChI:InChI=1/C58H97N15O17/c1-12-30(10)39-53(85)71-40(31(11)75)52(84)64-24-38(76)69-42(45(78)47(60)79)55(87)68-37(25-74)57(89)90-46(32-17-14-13-15-18-32)43(73-51(83)36(23-28(6)7)66-48(80)33(59)21-26(2)3)56(88)72-41(44(77)29(8)9)54(86)67-35(22-27(4)5)50(82)65-34(49(81)70-39)19-16-20-63-58(61)62/h13-15,17-18,26-31,33-37,39-46,74-75,77-78H,12,16,19-25,59H2,1-11H3,(H2,60,79)(H,64,84)(H,65,82)(H,66,80)(H,67,86)(H,68,87)(H,69,76)(H,70,81)(H,71,85)(H,72,88)(H,73,83)(H4,61,62,63)
118374-47-3Relevant articles and documents
Total synthesis of lysobactin
Guzman-Martinez, Aikomari,Lamer, Ryan,VanNieuwenhze, Michael S.
, p. 6017 - 6021 (2008/02/04)
Antibiotic resistance has become a significant public health concern. Antibiotics that belong to new structural classes and manifest their biological activity via novel mechanisms are urgently needed. Lysobactin, a depsipeptide antibiotic has displayed very strong antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) as well as vancomycin-resistant enterococci (VRE) with minimum inhibitory concentrations (MICs) ranging from 0.39 to 0.78 μg/mL. The MIC values against VRE were more than 50-fold lower than those reported for vancomycin itself. Lysobactin was found to inhibit nascent peptidoglycan formation; however, this activity was not antagonized in the presence of N-acyl-L-Lys-D-Ala-D-Ala, the binding domain on the cell wall precursors that is utilized by vancomycin. Thus, lysobactin represents a promising agent for the treatment bacterial infections due to resistant pathogens. We describe a convergent synthesis of lysobactin that relies upon a highly efficient macrocyclization reaction to assemble the 28-membered cyclic depsipeptide. This synthesis provides the foundation for further study of the mode of action utilized by lysobactin and its analogues.
